Opioids Purdue’s move could create some leverage if there’s an eventual settlement and may help the company as it argues for a lower payment. (Photo: Shutterstock)

Purdue Pharma LP’s decision to stop promoting its opioid drugs to doctors is being hailed as the first result of a judge’s push for concrete solutions to a nationwide epidemic, even though the company says the move has nothing to do with a massive lawsuit against drugmakers.

On Feb. 9 Purdue announced it would lay off 200 salespeople and halt marketing of its much-abused OxyContin painkiller in doctors’ offices, a week after U.S. District Judge Dan Polster in Cleveland met with drugmakers fighting hundreds of opioid lawsuits filed by cities and counties.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.